The overall goal of our current research is to develop novel treatments and drug delivery methodologies for presently untreatable, socially significant conditions involving CNS and meninges, such as meningeal and brain cancer, neurodegenerative diseases, trauma, infections and enzyme deficiencies. Hypothetically, the initial bolus translocation in the CSF is hydrostatically controlled, and the subsequent solute transport in the cerebrospinal fluid (CSF) is governed by active biomechanical remixing (and not by directional flows or diffusion). Solutes are thus delivered to entrances of liquid conduits enveloping the arteries and veins leading into the CNS (Virchow-Robin spaces). The periarterial conduits are rapidly remixed along the arterial axes due to the pulsation of the arteries. The data clearly shows that the boundaries of the periarterial conduits are penetrable for solutes, including large molecules. Thus, solutes administered to the CSF have direct access to all compartments of CNS parenchyma. The final outcome of the leptomeningeal drug transport will depend on the solute (e.g., drug) behavior in each of the above transport processes, none of which has been studied systematically. The effects of physiological factors on drug transport in the CSF may depend on the presence of pathologies, such as inflammation and tumors. Optimization of a drug molecule or a drug delivery system for certain behavior in each of the transport processes is expected to enable preferential routing to a desirable subcompartment of either CNS or meninges. However, lack of quantitative mechanistic knowledge on the hydrostatic and hydrodynamic solute translocation in the CSF hinder the development of novel drugs optimized for delivery through the CSF. The objectives of the proposed work are (a) to investigate the mechanisms of hydrostatic bolus translocation and the subsequent hydrodynamically driven solute transport, and (b) to compose and test a mechanistic pharmacokinetic model suitable for drug development. The studies will be carried out in rodents and in non-human primates. Impact. The study will result in new physiological knowledge and novel approaches facilitating drug development for presently untreatable conditions involving CNS and meninges.

Public Health Relevance

This study is intended to investigate the hydrostatic and hydrodynamic factors regulating transport processes in the cerebrospinal fluid, which will help developing new approaches for delivery of therapies, in particular biopharmaceuticals, to the central nervous system and meninges. This will provide novel effective therapies for diseases involving these tissues, such as, Parkinson's and Alzheimer's diseases, inherited genetic deficiencies, brain cancer and neoplastic meningitis.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
1R01NS092838-01
Application #
8944795
Study Section
Gene and Drug Delivery Systems Study Section (GDD)
Program Officer
Koenig, James I
Project Start
2015-05-01
Project End
2018-04-30
Budget Start
2015-05-01
Budget End
2016-04-30
Support Year
1
Fiscal Year
2015
Total Cost
$511,798
Indirect Cost
$208,893
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02114